Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
53.34
-0.66 (-1.22%)
Delayed Quote
Updated: 1:12 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
37
38
Next >
2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street
↗
October 05, 2023
The analysts who follow these stocks have some big expectations for the year ahead.
Via
The Motley Fool
Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price
↗
October 04, 2023
Via
Benzinga
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
↗
October 03, 2023
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.
Via
InvestorPlace
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
↗
October 03, 2023
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.
Via
The Motley Fool
2 Top Biotech Stocks to Buy in October
↗
October 03, 2023
Growth catalysts lie ahead for both of these players.
Via
The Motley Fool
2 Bargain Growth Stocks to Buy Hand Over Fist
↗
September 28, 2023
Both stocks have declined in recent times.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
↗
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
↗
October 01, 2023
These companies are helping change medicine; they could make boatloads of money along the way.
Via
The Motley Fool
3 Cathie Wood Stocks Set to Explode Higher
↗
October 01, 2023
Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.
Via
InvestorPlace
Futurescape: Betting Big on These 3 Next-Gen Tech Stocks
↗
October 01, 2023
These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.
Via
InvestorPlace
3 No-Brainer Growth Stocks to Buy in October
↗
October 01, 2023
These three top mid-cap stocks could be poised for a long-tailed growth spurt.
Via
The Motley Fool
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
↗
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
↗
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
↗
September 29, 2023
These stocks have what it takes to grow in leaps and bounds.
Via
The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
↗
September 28, 2023
The FDA is within three months of making a decision on the first-ever CRISPR-based drug.
Via
Investor's Business Daily
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
↗
September 27, 2023
These pharma stocks could boom in the coming years, riding their diversified pipelines with massive addressable markets higher.
Via
InvestorPlace
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
↗
September 27, 2023
Are you looking to invest in undervalued stocks? Here are sever undervalued stocks with sparkling prospects.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
↗
September 27, 2023
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
↗
September 24, 2023
These two high-tech stocks could dramatically outperform the broader market in the years ahead.
Via
The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
↗
September 21, 2023
I favor holding onto these players for the long term to truly benefit from their earnings potential.
Via
The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
↗
September 20, 2023
These two biotechs have a lot in common, but one is much better capitalized.
Via
The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Where Will CRISPR Therapeutics Be in 5 Years?
↗
September 19, 2023
The company hasn't performed well in the past five years, but things could change.
Via
The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
↗
September 19, 2023
Good medicines aren't always good business.
Via
The Motley Fool
2 Top Trends to Invest $500 In Right Now
↗
September 18, 2023
Early investors in these trends may reap the rewards over time.
Via
The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
↗
September 17, 2023
Catalysts on the horizon could drive gains in these top stocks.
Via
The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
↗
September 16, 2023
The returns are impressive, but will they continue to be so?
Via
The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
↗
September 15, 2023
They're both liable to grow by a lot, but one of them is a safer bet in the near term.
Via
The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
↗
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
37
38
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
